news
Biogen refocuses its Alzheimer’s strategy
Part of Biogen’s prioritisation of its portfolio includes focusing on the advancement of its leading anti-amyloid beta Alzheimer’s treatment, LEQEMBI® (lecanemab-irmb).
List view / Grid view
Eisai
article
Market outlook to 2032: future trends across the seven major markets
Challenges such as market exclusivity and patient treatment preference are expected to shape the insomnia and Gaucher disease therapy landscape in the seven major markets (7MM) in 2032, research predicts.
news
Research predicts 2029 small molecule oncology market leaders
With over $7 billion sales predicted by 2029, AstraZeneca’s Tagrisso is set to lead the lung cancer small molecule treatment market, according to GlobalData.
article
Learning from lecanemab: a breakthrough treatment
Here, Dr Michael Irizarry, Eisai’s Senior Vice President of Clinical Research and Deputy Chief Clinical Officer for Alzheimer’s Disease and Brain Health discusses its highly anticipated Alzheimer’s drug, lecanemab.
news
Eisai submits MAA for lecanemab in Europe
A Marketing Authorisation Application for lecanemab to treat Alzheimer's has been submitted to the European Medicines Agency.
news
Potential blockbuster drugs to watch in 2023
Lecanemab for Alzheimer's and the first potential gene therapy primed for US launch for haemophilia A are two potential blockbuster Drugs to Watch™, says a 2023 report.
news
FDA grants accelerated approval for Leqembi
Alzheimer’s drug Leqembi has been accepted via the US Food and Drug Administration (FDA)’s Accelerated Approval pathway.
news
Collaboration promotes sustainable pharmaceutical packaging
Four Japanese pharmaceutical companies agree to collaborate on promoting more sustainable pharmaceutical packaging.
news
NEJM publishes lecanemab Alzheimer’s study results
Full study results of Eisai’s Phase III Alzheimer's study suggest lecanemab could slow disease progression.
news
Lecanemab diminishes mental deterioration in early Alzheimer’s
Phase III trial confirmed Eisai’s lecanemab significantly decreased cognitive decline in patients with mild Alzheimer’s disease.
news
Lenvima plus Keytruda achieves primary endpoints in trial for RCC
Lenvima and Keytruda has demonstrated positive top-line results in a Phase III trial in patients with advanced renal cell carcinoma.
news
Novel anti-amyloid drug BAN2401 enters Phase III trial in Alzheimer’s patients
BAN2401 will be tested in various stages of Alzheimer’s disease progression to assess if it can slow the progression of cognitive decline.
news
FDA requests market withdrawal of weight-loss drug Belviq
After clinical trials showed an increased risk of cancer in patients taking Belviq, the FDA has recommended the withdrawal of the drug from the US market.
news
Life-extending breast cancer drug approved by NICE
3 November 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE has said eribulin, which is also called Halaven and made by Eisai, should be an option for people with locally advanced or metastatic breast cancer...
news
ESMO 2016: New data from Eisai’s oncology portfolio for halaven (eribulin), lenvima (lenvatinib) and kisplyx (lenvatinib)
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
European Pharmaceutical Review will of course keep you up to date with all the latest pharma news from the conference. Here's a preview snippet...
